CN110448659A - Sea-buckthorn protect liver process for preparing buccal lozenge - Google Patents
Sea-buckthorn protect liver process for preparing buccal lozenge Download PDFInfo
- Publication number
- CN110448659A CN110448659A CN201810427287.4A CN201810427287A CN110448659A CN 110448659 A CN110448659 A CN 110448659A CN 201810427287 A CN201810427287 A CN 201810427287A CN 110448659 A CN110448659 A CN 110448659A
- Authority
- CN
- China
- Prior art keywords
- lozenge
- buckthorn
- sea
- vitamin
- protect liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007937 lozenge Substances 0.000 title claims abstract description 78
- 210000004185 liver Anatomy 0.000 title claims abstract description 57
- 235000003145 Hippophae rhamnoides Nutrition 0.000 title claims abstract description 49
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 18
- 240000000950 Hippophae rhamnoides Species 0.000 title abstract 4
- 239000004615 ingredient Substances 0.000 claims abstract description 44
- 239000002245 particle Substances 0.000 claims abstract description 32
- 238000001514 detection method Methods 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 27
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 26
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 26
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 24
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 18
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 15
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 15
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 14
- 240000007817 Olea europaea Species 0.000 claims abstract description 14
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 14
- 244000269722 Thea sinensis Species 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 14
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 13
- 239000004475 Arginine Substances 0.000 claims abstract description 13
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004471 Glycine Substances 0.000 claims abstract description 13
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 13
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 13
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 13
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 13
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 13
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 13
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 13
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 13
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 13
- 239000011718 vitamin C Substances 0.000 claims abstract description 13
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 13
- 239000011709 vitamin E Substances 0.000 claims abstract description 13
- 229940046009 vitamin E Drugs 0.000 claims abstract description 13
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 12
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 12
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 12
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960002477 riboflavin Drugs 0.000 claims abstract description 12
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 12
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 12
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 12
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 12
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 12
- 238000012797 qualification Methods 0.000 claims abstract description 11
- 235000018417 cysteine Nutrition 0.000 claims abstract description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 238000012360 testing method Methods 0.000 claims abstract description 9
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims abstract description 9
- 235000006076 zinc citrate Nutrition 0.000 claims abstract description 9
- 239000011746 zinc citrate Substances 0.000 claims abstract description 9
- 229940068475 zinc citrate Drugs 0.000 claims abstract description 9
- 244000164480 Curcuma aromatica Species 0.000 claims abstract 4
- 240000006079 Schisandra chinensis Species 0.000 claims abstract 4
- 241000229143 Hippophae Species 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 22
- 238000001035 drying Methods 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 235000009697 arginine Nutrition 0.000 claims description 12
- 235000004554 glutamine Nutrition 0.000 claims description 11
- 210000000697 sensory organ Anatomy 0.000 claims description 11
- 238000005469 granulation Methods 0.000 claims description 10
- 230000003179 granulation Effects 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000011122 softwood Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000004973 liquid crystal related substance Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims 2
- 244000163122 Curcuma domestica Species 0.000 description 11
- 241000736075 Schisandra Species 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 235000013616 tea Nutrition 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 208000004930 Fatty Liver Diseases 0.000 description 6
- 206010019708 Hepatic steatosis Diseases 0.000 description 6
- 208000010706 fatty liver disease Diseases 0.000 description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 description 6
- 244000019459 Cynara cardunculus Species 0.000 description 4
- 235000019106 Cynara scolymus Nutrition 0.000 description 4
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 244000131522 Citrus pyriformis Species 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of sea-buckthorn protect liver process for preparing buccal lozenge, the following steps are included: S1: raw material preparation: raw material is grouped as by the group of following weight percentage: major ingredient: sea-buckthorn 3.5%~5%, chlorogenic acid 5%~9%, tea polyphenols 1.5%~3%, Schisandra chinens P.E 2%~4%, olive extract 0.9%~1.5% and curcuma powder 3%~7%, ingredient: glycine 0.15%~0.3%, glutamine 0.07%~0.12%, cysteine 0.06%~0.14%, arginine 0.08%~0.1%, vitamin C 1.2%~2.5%, vitamin E 1.1%~1.3%, vitamin B2 0.09%~0.15%, vitamin B6 0.12%~0.15%, zinc citrate 2%~3 .5%, and to the quality of raw material detect, detection qualification can use.The present invention is by detecting the moisture in particle and lozenge, and test to many index of lozenge, can find in time the product of inferior quality and reject, prevent the product of inferior quality from coming into the market during sea-buckthorn protect liver lozenge producing.
Description
Technical field
The present invention relates to sea-buckthorn protect liver lozenge preparation technical field more particularly to a kind of sea-buckthorn protect liver process for preparing buccal lozenge.
Background technique
Liver is human internal organ name, and one of the five internal organs are an organs in vertebrate body based on metabolic function, and
It sufficiently plays deoxidation inside body, stores glycogen, synthesis of secreted protein etc. occurs many currently on the market
Protect liver nutrient tablet, for example ground by Beijing Yin Hui biochemical technology Co., Ltd and U.S. SilverBeamBiopharmLtd.Co.
Study carefully the net nutrient tablet of liver of mechanism research and development, main ingredient: the net nutrient tablet of liver: turmeric, glycine, glutamine, cysteine, smart ammonia
Acid, vitamin C, vitamin E, vitamin B2, vitamin B6, zinc citrate etc.；The net nutrient tablet of liver increases liver cell synthesis and carries rouge
For albumen ability to accelerate fat and triglycerides to transport, liver inhibits the release of tumor necrosis factor TNF-a only.Avoid TNF-a
Causing insulin resistance, reduction lipolysis is free fatty acid, thus inhibit triglycerides in the synthesis and accumulation of liver, by
Vitamin C and vitamin E and microelement it is special " platinum combination " play superpower anti-oxidation characteristics, more effectively remove and cause
The peroxide and living radical of Oxidative Damage in Liver, avoid liver cell from being damaged and wounded hepatocytes are promoted to restore, provide
Amino acid-glutamic acid, cysteine and the glycine of fabricated in situ glutathione.Glutathione can protect liver cell and inhibition
The formation of alcohol fatty liver, the extraordinary amino acid (such as arginine) that supplement Patients with Fatty Liver lacks, Patients with Fatty Liver albumen generation
Thank impaired, certain special type amino acid can not synthesize in vivo, therefore could only be obtained by exogenous supplement, research shows that long
Phase, which eats the food that arginine lacks, can lead to fatty liver, the net nutritional ingredient of liver can by inhibit Kupffer cell conversion growth because
The release of sub- TGF-b avoids causing Hepatic Stellate Cell Activation, so that fatty liver fibrosis and cirrhosis are prevented, a variety of B race dimension lifes
Element and trace element zinc compounding more effectively can selectively supplement liver nutrition, avoid liver overnutrition, sugar-free formulation and
Without any animal composition, diabetes and Patients with Fatty Liver, liver net energy is suitble to enough to increase the immunization of human body, existing protect liver
Lozenge mostly will not detect the indices of lozenge, cause the quality of lozenge lower, people takes during preparation
Effect reduces much afterwards.
Summary of the invention
Technical problems based on background technology, the invention proposes sea-buckthorn protect liver process for preparing buccal lozenge.
Sea-buckthorn protect liver process for preparing buccal lozenge proposed by the present invention, comprising the following steps:
S1: raw material preparation: raw material is grouped as by the group of following weight percentage: major ingredient: sea-buckthorn 3.5%~5%, chlorogenic acid 5%~
9%, tea polyphenols 1.5%~3%, Schisandra chinens P.E 2%~4%, olive extract 0.9%~1.5% and curcuma powder 3%~7%, ingredient:
Glycine 0.15%~0.3%, glutamine 0.07%~0.12%, cysteine 0.06%~0.14%, arginine 0.08%~
0.1%, vitamin C 1.2%~2.5%, vitamin E 1.1%~1.3%, vitamin B2 0.09%~0.15%, vitamin B6
0.12%~0.15%, zinc citrate 2%~3.5%, and the quality of raw material is detected, detection qualification can use；
S2: raw material mixing: chlorogenic acid described in S1, tea polyphenols, Schisandra chinens P.E, olive extract and curcuma powder are mixed
Close, and ethanol solution be added and stirs evenly obtained major ingredient mixture, and by glycine, glutamine, cysteine, arginine,
Vitamin C, vitamin E, vitamin B2, vitamin B6 and zinc citrate are mixed, and ingredients mixture are made, and major ingredient is mixed
It closes object and ingredients mixture is mixed；
S3: it softwood processed: to addition sea-buckthorn inspissated juice in major ingredient described in S2 and ingredients mixture, and stirs evenly, is made soft
Material；
S4: it granulation: is pelletized using mesh to softwood described in S3, puts particle obtained into drying box after the completion of granulation
It is inside dried, drying temperature is 65 DEG C, drying time 120min, after drying, is carried out to the moisture content in particle
Detection, detection qualification can carry out next process；
S5: tabletting: after the particle detections described in the S4 are qualified, magnesium stearate is added on particle and mixes, carries out tabletting, is made
Lozenge；
S6: lozenge is examined: testing to lozenge described in S5, sense organ, net content, slice weight, moisture content are not met and wanted
Lozenge ask and impure is rejected, and can be prepared by sea-buckthorn protect liver lozenge after the assay was approved；
S7: packaging: the sea-buckthorn protect liver lozenge described in the S6 is packed, and packaged finished product need to be through sense organ, physics and chemistry, microorganism
After detection is qualified, warehouse for finished product and outbound sale can be entered.
Preferably, it in the S1, when preparing raw material, needs to be filtered the impurity in raw material.
Preferably, in the S2, when being mixed, by chlorogenic acid, tea polyphenols, Schisandra chinens P.E, olive extract
It successively puts into agitator tank and is mixed with curcuma powder, and to agitator tank into heating.
Preferably, in the S4, microwave method is utilized by microwave moisture instrument, is propagated after passing through particle by detection microwave
The different variations that spread speed and intensity on direction can occur are to calculate the moisture content in material, and microwave signal is by transmitting day
Line transmitting is received by corresponding receiving antenna after passing through particle, by accurately analyzing the microwave signal after particle, is pushed away
The mass fraction for exporting water in particle, exports when by fructufy and shows on liquid crystal display interface, carries out to the moisture in particle
Detection.
Preferably, in the S6, when carrying out organoleptic examination, the size, color, surface flatness of lozenge are seen
It examines, sifts out underproof lozenge, test also with microwave moisture instrument to the moisture in lozenge.
Preferably, in the S7, when packaging, sea-buckthorn protect liver lozenge is put and irradiates 15min under ultraviolet light, after the completion of irradiation
Sea-buckthorn protect liver lozenge is packed in time.
Preferably, in the S6, sea-buckthorn protect liver is checked containing sheet hardness, lozenge is placed on hardness tester, after zero
Gradually, it is slowly increased pressure, until lozenge is crushed, dial reading is read, obtains the hardness of lozenge.
Preferably, in the S6, when tablet weight variation is examined, 26 tablets of lozenges are taken, accurately weighed every slice weight simultaneously acquires flat
Equal slice weight, then with every slice weight compared with average slice weight, the tablet beyond difference limit must not be more than 2, and must not have one
1 times of piece overrun.
Beneficial effects of the present invention: by sea-buckthorn protect liver lozenge produce during, to the moisture in particle and lozenge
It is detected, and is tested to many index of lozenge, can find in time the product of inferior quality and rejected, prevent product of inferior quality stream
Enter market.
Specific embodiment
Combined with specific embodiments below the present invention is made further to explain.
Embodiment one
Sea-buckthorn protect liver process for preparing buccal lozenge is proposed in the present embodiment, comprising the following steps:
S1: raw material preparation: raw material is grouped as by the group of following weight percentage: major ingredient: sea-buckthorn 3%, chlorogenic acid 5%, tea polyphenols 1%,
Schisandra chinens P.E 2%, olive extract 0.9% and curcuma powder 3%, ingredient: glycine 0.15%, glutamine 0.07%, half Guang ammonia
Sour 0.06%, arginine 0.08, vitamin C 1.2%, vitamin E 1.1%, vitamin B2 0.09%, vitamin B6 0.12%, lemon
Lemon acid zinc 2%, and the quality of raw material is detected, detection qualification can use；
S2: raw material mixing: chlorogenic acid described in S1, tea polyphenols, Schisandra chinens P.E, olive extract and curcuma powder are mixed
Close, and ethanol solution be added and stirs evenly obtained major ingredient mixture, and by glycine, glutamine, cysteine, arginine,
Vitamin C, vitamin E, vitamin B2, vitamin B6 and zinc citrate are mixed, and ingredients mixture are made, and major ingredient is mixed
It closes object and ingredients mixture is mixed；
S3: it softwood processed: to addition sea-buckthorn inspissated juice in major ingredient described in S2 and ingredients mixture, and stirs evenly, is made soft
Material；
S4: it granulation: is pelletized using mesh to softwood described in S3, puts particle obtained into drying box after the completion of granulation
It is inside dried, drying temperature is 65 DEG C, drying time 120min, after drying, is carried out to the moisture content in particle
Detection, detection qualification can carry out next process；
S5: tabletting: after the particle detections described in the S4 are qualified, magnesium stearate is added on particle and mixes, carries out tabletting, is made
Lozenge；
S6: lozenge is examined: testing to lozenge described in S5, sense organ, net content, slice weight, moisture content are not met and wanted
Lozenge ask and impure is rejected, and can be prepared by sea-buckthorn protect liver lozenge after the assay was approved；
S7: packaging: the sea-buckthorn protect liver lozenge described in the S6 is packed, and packaged finished product need to be through sense organ, physics and chemistry, microorganism
After detection is qualified, warehouse for finished product and outbound sale can be entered.
Globe artichoke is a kind of health-care vegetable with high nutrition, often edible to protect liver kidney and enhancing liver toxin expelling function
Can, have and amino acid metabolism reduction cholesterol indigestion improvement gastrointestinal function is promoted to prevent artery sclerosis protection cardiovascular
And other effects, and it is the activity wherein to work that clinic, which shows that high dose globe artichoke will not bring adverse reaction polyphenols,
One of ingredient has such as globe artichoke and is depressured a variety of physiological functions such as antitumor enhancing immunity of organism protection liver according to another report
It points out, globe artichoke has the function of that good anti-hepatic fibrosis, tea polyphenols are green-tea extracts, to the slow of the inductions such as drug alcohol
Property hepatic injury have a protective effect, Schisandra chinens P.E has the various actives such as protecting liver, lowering enzymes；Olive extract, which has, increases antioxygen
Change the activity with liver detoxification；Curcumin in curcuma powder, which has the effects that anti-oxidant inhibition growth of tumour cell is anti-inflammatory, research
Point out, using curcumin to liver cancer cell lines handle can specificity inhibit cancer stem cell to grow, and to NF-kB and
Two bars approach of HDAC carries out joint inhibition, and this may be the available strategy that treatment has the hepatocarcinoma patient of poor prognosis.
Embodiment two
Sea-buckthorn protect liver process for preparing buccal lozenge is proposed in the present embodiment, comprising the following steps:
S1: raw material preparation: raw material is grouped as by the group of following weight percentage: major ingredient: sea-buckthorn 4%, chlorogenic acid 7%, tea polyphenols 2%,
Schisandra chinens P.E 2.5%, olive extract 1.2% and curcuma powder 5%, ingredient: glycine 0.23%, glutamine 0.09%, half Guang
Propylhomoserin 0.08%, arginine 0.09%, vitamin C 2%, vitamin E 1.2%, vitamin B2 0.1%, vitamin B6 0.14%, lemon
Lemon acid zinc 2.9%, and the quality of raw material is detected, detection qualification can use；
S2: raw material mixing: chlorogenic acid described in S1, tea polyphenols, Schisandra chinens P.E, olive extract and curcuma powder are mixed
Close, and ethanol solution be added and stirs evenly obtained major ingredient mixture, and by glycine, glutamine, cysteine, arginine,
Vitamin C, vitamin E, vitamin B2, vitamin B6 and zinc citrate are mixed, and ingredients mixture are made, and major ingredient is mixed
It closes object and ingredients mixture is mixed；
S3: it softwood processed: to addition sea-buckthorn inspissated juice in major ingredient described in S2 and ingredients mixture, and stirs evenly, is made soft
Material；
S4: it granulation: is pelletized using mesh to softwood described in S3, puts particle obtained into drying box after the completion of granulation
It is inside dried, drying temperature is 65 DEG C, drying time 120min, after drying, is carried out to the moisture content in particle
Detection, detection qualification can carry out next process；
S5: tabletting: after the particle detections described in the S4 are qualified, magnesium stearate is added on particle and mixes, carries out tabletting, is made
Lozenge；
S6: lozenge is examined: testing to lozenge described in S5, sense organ, net content, slice weight, moisture content are not met and wanted
Lozenge ask and impure is rejected, and can be prepared by sea-buckthorn protect liver lozenge after the assay was approved；
S7: packaging: the sea-buckthorn protect liver lozenge described in the S6 is packed, and packaged finished product need to be through sense organ, physics and chemistry, microorganism
After detection is qualified, warehouse for finished product and outbound sale can be entered.
Embodiment three
Sea-buckthorn protect liver process for preparing buccal lozenge is proposed in the present embodiment, comprising the following steps:
S1: raw material preparation: raw material is grouped as by the group of following weight percentage: major ingredient: sea-buckthorn 5%, chlorogenic acid 9%, tea polyphenols 3%,
Schisandra chinens P.E 4%, olive extract 1.5% and curcuma powder 7%, ingredient: glycine 0.3%, glutamine 0.12%, half Guang ammonia
Sour 0.14%, arginine 0.1%, vitamin C 2.5%, vitamin E 1.3%, vitamin B2 0.15%, vitamin B6 0.15%, lemon
Lemon acid zinc 3.5%, and the quality of raw material is detected, detection qualification can use；
S2: raw material mixing: chlorogenic acid described in S1, tea polyphenols, Schisandra chinens P.E, olive extract and curcuma powder are mixed
Close, and ethanol solution be added and stirs evenly obtained major ingredient mixture, and by glycine, glutamine, cysteine, arginine,
Vitamin C, vitamin E, vitamin B2, vitamin B6 and zinc citrate are mixed, and ingredients mixture are made, and major ingredient is mixed
It closes object and ingredients mixture is mixed；
S3: it softwood processed: to addition sea-buckthorn inspissated juice in major ingredient described in S2 and ingredients mixture, and stirs evenly, is made soft
Material；
S4: it granulation: is pelletized using mesh to softwood described in S3, puts particle obtained into drying box after the completion of granulation
It is inside dried, drying temperature is 65 DEG C, drying time 120min, after drying, is carried out to the moisture content in particle
Detection, detection qualification can carry out next process；
S5: tabletting: after the particle detections described in the S4 are qualified, magnesium stearate is added on particle and mixes, carries out tabletting, is made
Lozenge；
S6: lozenge is examined: testing to lozenge described in S5, sense organ, net content, slice weight, moisture content are not met and wanted
Lozenge ask and impure is rejected, and can be prepared by sea-buckthorn protect liver lozenge after the assay was approved；
S7: packaging: the sea-buckthorn protect liver lozenge described in the S6 is packed, and packaged finished product need to be through sense organ, physics and chemistry, microorganism
After detection is qualified, warehouse for finished product and outbound sale can be entered.
The sea-buckthorn protect liver lozenge as made from embodiment one, embodiment two and embodiment three and traditional production method phase
Than it is as follows to improve mass percent:
| Embodiment | One | Two | Three |
| Improve percentage | 85% | 95% | 80% |
By above table it is found that the preparation method of sea-buckthorn protect liver lozenge proposed by the present invention improves the matter of sea-buckthorn protect liver lozenge
Amount, and embodiment two is most preferred embodiment.
The foregoing is only a preferred embodiment of the present invention, but scope of protection of the present invention is not limited thereto,
Anyone skilled in the art in the technical scope disclosed by the present invention, according to the technique and scheme of the present invention and its
Inventive concept is subject to equivalent substitution or change, should be covered by the protection scope of the present invention.
Claims (8)
1. sea-buckthorn protect liver process for preparing buccal lozenge, which comprises the following steps:
S1: raw material preparation: raw material is grouped as by the group of following weight percentage: major ingredient: sea-buckthorn 3.5%~5%, chlorogenic acid 5%~
9%, tea polyphenols 1.5%~3%, Schisandra chinens P.E 2%~4%, olive extract 0.9%~1.5% and curcuma powder 3%~7%, ingredient:
Glycine 0.15%~0.3%, glutamine 0.07%~0.12%, cysteine 0.06%~0.14%, arginine 0.08%~
0.1%, vitamin C 1.2%~2.5%, vitamin E 1.1%~1.3%, vitamin B2 0.09%~0.15%, vitamin B6
0.12%~0.15%, zinc citrate 2%~3.5%, and the quality of raw material is detected, detection qualification can use；
S2: raw material mixing: chlorogenic acid described in S1, tea polyphenols, Schisandra chinens P.E, olive extract and curcuma powder are mixed
Close, and ethanol solution be added and stirs evenly obtained major ingredient mixture, and by glycine, glutamine, cysteine, arginine,
Vitamin C, vitamin E, vitamin B2, vitamin B6 and zinc citrate are mixed, and ingredients mixture are made, and major ingredient is mixed
It closes object and ingredients mixture is mixed；
S3: it softwood processed: to addition sea-buckthorn inspissated juice in major ingredient described in S2 and ingredients mixture, and stirs evenly, is made soft
Material；
S4: it granulation: is pelletized using mesh to softwood described in S3, puts particle obtained into drying box after the completion of granulation
It is inside dried, drying temperature is 65 DEG C, drying time 120min, after drying, is carried out to the moisture content in particle
Detection, detection qualification can carry out next process；
S5: tabletting: after the particle detections described in the S4 are qualified, magnesium stearate is added on particle and mixes, carries out tabletting, is made
Lozenge；
S6: lozenge is examined: testing to lozenge described in S5, sense organ, net content, slice weight, moisture content are not met and wanted
Lozenge ask and impure is rejected, and can be prepared by sea-buckthorn protect liver lozenge after the assay was approved；
S7: packaging: the sea-buckthorn protect liver lozenge described in the S6 is packed, and packaged finished product need to be through sense organ, physics and chemistry, microorganism
After detection is qualified, warehouse for finished product and outbound sale can be entered.
2. sea-buckthorn protect liver process for preparing buccal lozenge according to claim 1, which is characterized in that in the S1, preparing raw material
When, it needs to be filtered the impurity in raw material.
3. sea-buckthorn protect liver process for preparing buccal lozenge according to claim 1, which is characterized in that in the S2, mixed
When, chlorogenic acid, tea polyphenols, Schisandra chinens P.E, olive extract and curcuma powder are successively put into carry out mixing in agitator tank and stirred
It mixes, and to agitator tank into heating.
4. sea-buckthorn protect liver process for preparing buccal lozenge according to claim 1, which is characterized in that in the S4, pass through Microwave Water
Instrument is divided to utilize microwave method, the difference that can occur by detecting spread speed and intensity of the microwave after passing through particle on the direction of propagation
To calculate the moisture content in material, microwave signal is emitted by transmitting antenna for variation, after passing through particle, by corresponding receiving antenna
It receives, by accurately analyzing the microwave signal after particle, derives the mass fraction of water in particle, it is defeated when by fructufy
It out and is shown on liquid crystal display interface, the moisture in particle is detected.
5. sea-buckthorn protect liver process for preparing buccal lozenge according to claim 1, which is characterized in that in the S6, carrying out sense organ
When inspection, the size, color, surface flatness of lozenge are observed, underproof lozenge is sifted out, also with microwave moisture
Instrument tests to the moisture in lozenge.
6. sea-buckthorn protect liver process for preparing buccal lozenge according to claim 1, which is characterized in that, will be husky when packaging in the S7
Spine protect liver lozenge is put irradiates 15min under ultraviolet light, packs in time to sea-buckthorn protect liver lozenge after the completion of irradiation.
7. sea-buckthorn protect liver process for preparing buccal lozenge according to claim 1, which is characterized in that in the S6, to sea-buckthorn protect liver
Checked containing sheet hardness, lozenge be placed on hardness tester, after zero gradually, be slowly increased pressure, until lozenge is crushed, read
Dial reading is taken, obtains the hardness of lozenge.
8. sea-buckthorn protect liver process for preparing buccal lozenge according to claim 1, which is characterized in that in the S6, tablet weight variation inspection
When testing, 26 tablets of lozenges are taken, accurately weighed every slice weight simultaneously acquires average slice weight, then with every slice weight and average slice weight ratio
Compared with the tablet beyond difference limit must not be more than 2, and must not have 1 times of a piece of overrun.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810427287.4A CN110448659A (en) | 2018-05-07 | 2018-05-07 | Sea-buckthorn protect liver process for preparing buccal lozenge |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810427287.4A CN110448659A (en) | 2018-05-07 | 2018-05-07 | Sea-buckthorn protect liver process for preparing buccal lozenge |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110448659A true CN110448659A (en) | 2019-11-15 |
Family
ID=68472170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810427287.4A Pending CN110448659A (en) | 2018-05-07 | 2018-05-07 | Sea-buckthorn protect liver process for preparing buccal lozenge |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110448659A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113143962A (en) * | 2021-05-11 | 2021-07-23 | 四川九章生物科技有限公司 | A pharmaceutical composition for treating hyperlipidemia, and its preparation method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1623591A (en) * | 2003-12-04 | 2005-06-08 | 北京生物医药研究所 | Composition of pharmaceutical and preparation process thereof |
| CN103040057A (en) * | 2013-01-16 | 2013-04-17 | 中国农业大学 | Schisandra chinensis mixed beverage capable of relieving alcoholic liver injury and production technology thereof |
| CN103230422A (en) * | 2013-04-10 | 2013-08-07 | 广东工业大学 | A curcumin healthy granule and a preparation method thereof |
| CN103271393A (en) * | 2013-04-09 | 2013-09-04 | 广东工业大学 | Health care curcumin-sea-buckthorn beverage and preparation method thereof |
| CN107183716A (en) * | 2017-06-14 | 2017-09-22 | 北京希立康科技有限公司 | A kind of liver protection is dispelled wine health-care food composition and preparation method thereof |
-
2018
- 2018-05-07 CN CN201810427287.4A patent/CN110448659A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1623591A (en) * | 2003-12-04 | 2005-06-08 | 北京生物医药研究所 | Composition of pharmaceutical and preparation process thereof |
| CN103040057A (en) * | 2013-01-16 | 2013-04-17 | 中国农业大学 | Schisandra chinensis mixed beverage capable of relieving alcoholic liver injury and production technology thereof |
| CN103271393A (en) * | 2013-04-09 | 2013-09-04 | 广东工业大学 | Health care curcumin-sea-buckthorn beverage and preparation method thereof |
| CN103230422A (en) * | 2013-04-10 | 2013-08-07 | 广东工业大学 | A curcumin healthy granule and a preparation method thereof |
| CN107183716A (en) * | 2017-06-14 | 2017-09-22 | 北京希立康科技有限公司 | A kind of liver protection is dispelled wine health-care food composition and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 周凤春等: ""肝净"治疗脂肪肝的临床观察 ", 《家庭医药(医药论坛)》 * |
| 徐杨等: "金银花中绿原酸提取工艺的改进 ", 《甘肃医药》 * |
| 徐苏丽: "中药橄榄化学成分及药理作用研究进展", 《海峡药学》 * |
| 杨晓萍等: "茶多酚药理活性的研究进展 ", 《中央民族大学学报(自然科学版)》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113143962A (en) * | 2021-05-11 | 2021-07-23 | 四川九章生物科技有限公司 | A pharmaceutical composition for treating hyperlipidemia, and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101284772B1 (en) | Functional food composition with the effects of anti-inflammation and pain-relieving | |
| Złotek et al. | Potential in vitro antioxidant, anti-inflammatory, antidiabetic, and anticancer effect of arachidonic acid-elicited basil leaves | |
| Oliveira et al. | How does germinated rice impact starch structure, products and nutrional evidences?–A review | |
| Rao et al. | Protein characteristics, amino acid profile, health benefits and methods of extraction and isolation of proteins from some pseudocereals—a review | |
| Chen et al. | Nutritional, antioxidant, and quality characteristics of novel cookies enriched with mushroom (Cordyceps militaris) flour | |
| CN109349673A (en) | A kind of antarctic krill oil soft capsule peel, soft capsule and preparation method thereof | |
| Langyan et al. | Advancement in nutritional value, processing methods, and potential applications of Pseudocereals in dietary food: a review | |
| Li et al. | Acute and sub-chronic toxicity of glucose–cysteine Maillard reaction products in Sprague-Dawley rats | |
| Plustea et al. | Comparative Study of the Nutritional, Phytochemical, Sensory Characteristics and Glycemic Response of Cookies Enriched with Lupin Sprout Flour and Lupin Green Sprout | |
| CN110448659A (en) | Sea-buckthorn protect liver process for preparing buccal lozenge | |
| Kazemi et al. | Valorization of pistachio industrial waste: Simultaneous recovery of pectin and phenolics, and their application in low-phenylalanine cookies for phenylketonuria | |
| Lu et al. | From Palm to Plate: Unveiling the Potential of Coconut as a Plant-Based Food Alternative | |
| JP2004305202A (en) | Method for processing beverage given by using tartary buckwheat as raw material | |
| Pandey et al. | Box–Behnken design based statistical modelling to study the effects of spirulina (Arthrospira platensis) incorporation on nutritional standards of vegan snack product | |
| Erol et al. | A sustainable innovation: functionalization of pasta with methanol extract of turkish red pine (pinus brutia ten.) barks | |
| JP2014141438A (en) | Formulation, food and drink containing novel madeira vine product | |
| Bhatt et al. | Development of soluble dietary fiber incorporated black pea protein slice: Physicochemical, textural, and rheological properties | |
| Petchdee et al. | Cardiac protection of germinated brown rice extract in rabbit model of chronic myocardial infarction | |
| Pasha et al. | Biochemical, Nutritional and End Use Perspectives of Wheat Grass as Potential Dietary Supplement | |
| Chen et al. | Effect of red algae powder on gel properties and in vitro hypolipidemic activity of fish balls | |
| Šovljanski et al. | From Agricultural Waste to Functional Food Products: An Overview | |
| Preecharram et al. | Values, bioactive compound, antioxidant activities of brown rice and germinated brown rice, and the pellet products | |
| Baek et al. | Physicochemical and nutritional characteristics of vegan protein bars formulated with sweet potato and rice protein | |
| Sahan et al. | The Effect of Okra Seed (Abelmoschus esculentus) Powder Supplementation on Nutritional, Textural, Microstructural, and Sensory Properties of Gluten‐Free Muffins | |
| Ningrum et al. | Purple cabbage (Brassica oleracea L.) cookies as nutraceutical product for Maintaining Healthy Heart |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191115 |